Complement association with neurons and β-amyloid deposition in the brains of aged individuals with Down Syndrome

Neurobiology of Disease

Volumn 8, Issue 2, 2001, Pages 252-265

  Head, Elizabeth ^a   Azizeh, Bassem Y ^a   Lott, Ira T ^a   Tenner, Andrea J ^a   Cotman, Carl W ^a   Cribbs, David H ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Alzheimer's disease; C1q; Complement; Microglia; Neuroinflammation; Senile plaques; Trisomy 21; amyloid

Indexed keywords

AMYLOID BETA PROTEIN; COMPLEMENT COMPONENT C1; THIOFLAVINE;

ADULT; AGE; AGED; ALZHEIMER DISEASE; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DOWN SYNDROME; ENTORHINAL CORTEX; FEMALE; FRONTAL CORTEX; HIPPOCAMPUS; HUMAN; HUMAN TISSUE; INFLAMMATION; MALE; MICROGLIA; NEUROPATHOLOGY; PRIORITY JOURNAL; PROTEIN LOCALIZATION; SENILE PLAQUE; TRISOMY 21;

EID: 0035029836     PISSN: 09699961     EISSN: None     Source Type: Journal    
DOI: 10.1006/nbdi.2000.0380     Document Type: Article

References (64)

1. Localization and cell association of C1q in Alzheimer's disease brain
2. β-Amyloid (β/A4) deposition in the medial temporal lobe in Down's syndrome: Effects of brain region and patient age
3. Molecular dating of senile plaques in aged Down's syndrome and canine brains
4. Complement biosynthesis in the central nervous system
5. Neuropathological stageing of Alzheimer-related changes
6. Staging of Alzheimer's disease-related neurofibrillary changes
7. Morphometric analysis of microglia in Alzheimer's disease
8. Uptake, degradation, and release of fibrillar and soluble forms of Alzheimer's amyloid β-peptide by microglial cells
9. β-Amyloid converts an acute phase injury response to chronic injury responses
10. The neurobiologic consequences of Down syndrome
11. Immunoglobulins and complement factors in senile plaques
12. The role of complement and activated microglia in the pathogenesis of Alzheimer's disease
13. Microglia, scavenger receptors and the pathogenesis of Alzheimer's disease
14. Mini-mental state: A practical method for grading the cognitive status of patients for the clinician
15. Ultrastructure of the microglia that phagocytose amyloid and the microglia that produce beta-amyloid fibrils
16. Inflammatory pathogenesis in Alzheimer's disease: Biological mechanisms and cognitive sequeli
17. Complement expression in human brain. Biosynthesis of terminal pathway components and regulators in human glial cells and cell lines
18. Specific domains of β-amyloid from Alzheimer plaque elicit neuron killing in human microglia
19. Chemical characterization of Aβ17-42 peptide, a component of diffuse amyloid deposits of Alzheimer's disease
20. Brain interleukin I and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer's disease
21. Interleukin-1 expression in different plaque types in Alzheimer's disease, significance in plaque evolution
22. Age-related distribution of neuropathologic changes in the cerebral cortex of patients with Down's syndrome
23. Neuropathological changes in Down's syndrome hippocampal formation. Effect of age and apolipoprotein E genotype
24. Evidence of Amyloid β-protein immunoreactive early plaque lesions in Down's syndrome brains
25. Visualization of AB42(43) and AB40 in senile plaques with end-specific AB monoclonals: Evidence that an initially deposited species is AB42(43)
26. β-Amyloid activates complement by binding to a specific region of the collagen-like domain of C1qA chain
27. Complement mRNA in the mammalian brain: Responses to Alzheimer's disease and experimental brain lesioning
28. The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor
29. A prospective study of Alzheimer Disease in Down Syndrome
30. Sequence of deposition of heterogeneous amyloid beta-peptides and APOE in Down Syndrome: Implications for initial events in amyloid plaque formation
31. Early amyloid deposition in the medial temporal lobe of young Down syndrome patients: A regional quantitative analysis
32. Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease
33. Inflammation, A-beta deposition, and neurofibrillary tangle formation as correlates of Alzheimer's disease neurodegeneration
34. Microglia in diffuse plaques in hereditary cerebral hemorrhage with amyloidosis (Dutch). An immunohistochemical study
35. Down syndrome and Alzheimer's disease: Towards an understanding of pathogenesis
36. The pathological association between Down syndrome and Alzheimer disease
37. The pattern of acquisition of plaques and tangles in the brains of patients under 50 years of age with Down's syndrome
38. The inflammatory response system of brain: Implications for therapy of Alzheimer and other neurodegenerative diseases
39. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: A review of 17 epidemiological studies
40. Anti-inflammatory agents as a therapeutic approach to Alzheimer's disease
41. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease
42. Expression of complement in the brain: Role in health and disease
43. Inflammatory mechanisms in neurodegeneration and Alzheimer's disease: The role of the complement system
44. The involvement of astrocytes and an acute phase response in the amyloid deposition of Alzheimer's disease
45. Complement activation by β-amyloid in Alzheimer disease
46. A4 protein in Alzheimer's disease: Primary and secondary cellular events in extracellular amyloid deposition
47. Amyloid A4 and its precursor in Down's syndrome and Alzheimer's disease
48. Dominant and differential deposition of distinct beta-amyloid peptide species, A beta N3 (pE), in senile plaques
49. Normal and abnormal biology of the beta-amyloid precursor protein
50. Amyloid beta-protein and the genetics of Alzheimer's disease
51. Neuronal expression mRNAs for complement proteins of the classical pathway in Alzheimer brain
52. Neuritic plaque evolution in Alzheimer's disease is accompanied by transition of activated microglia from primed to enlarged to phagocytic forms
53. Increased complement biosynthesis by microglia and complement activation on neurons in Huntington's disease
54. Risk of Alzheimer's disease and duration of NSAID use
55. Temporal accrual of complement proteins in amyloid plaques in Down's syndrome with Alzheimer's disease
56. Neuroglial-mediated immunoinflammatory responses in Alzheimer's disease: Complement activation and therapeutic approaches
57. Neurons express proteins of the classical complement pathway in Alzheimer disease
58. Multivalent binding of complement protein C1q to the amyloid β-peptide promotes the nucleation phase of Aβ aggregation
59. Aggregation state-dependent activation of the classical complement pathway by amyloid beta peptide
60. Complement component C1q modulates the phagocytosis of Aβ by microglia
61. p, the C1q receptor that enhances phagocytosis
62. The role of perivascular and microglial cells in fibrillogenesis of beta-amyloid and PrP protein in Alzheimer's disease and scrapie
63. Occurrence of neuropathological changes and dementia of Alzheimer's disease in Down's syndrome
64. Mechanisms of neuronal degeneration in Alzheimer's disease